Syndecan-1 in multiple myeloma: Relationship to conventional prognostic factors

Hematology

Volumn 8, Issue 4, 2003, Pages 221-228

  Aref, Salah ^a   Goda, T ^a   El Sherbiny, M ^b  

^a MANSOURA UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Expression; Multiple myeloma; Prognosis; Syndecan 1

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; HEMOGLOBIN; SERUM ALBUMIN; SYNDECAN 1;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL PROLIFERATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMOGLOBIN DETERMINATION; HUMAN; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0141746184     PISSN: 10245332     EISSN: None     Source Type: Journal    
DOI: 10.1080/1024533031000153630     Document Type: Article

References (30)

1. Forester, J. and Paraskevas, F. (2000) In: Lee, G.R., Foerster, J., Lukens, J., Paraskevas, Greer, J.P. and Rodgers, G.M., eds, Multiple Myeloma in Wintrobe's Clinical Hematology (Williams & Wilkins Company Vol. 10, 99, pp 2631-2632.
2. Xu, J.L., Lai, R., Kinoshita, T., Nakashima, N. and Nagasaka, T. (2002) "Proliferation, apoptosis and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade", J. Clin. Pathol. 55(7), 530-534.
3. Kaneko, M., Kanda, Y., Oshima, K., Nannya, Y., Suguro, M., Yamamoto, R., Chizuka, A., Hamaki, T., Matsuyama, T., Takezako, N., Miwa, A. and Togowa, A. (2002) "Simple prognostic model for patients with multiple myeloma: a single center study in Japan", Ann. Hematol. 81, 33-36.
4. Tribalto, M., Amadori, S., Cudillo, L., Caravita, T., Del Poeta, G., Meloni, G., Avvisati, G., Petrucci, M.T., Pulosoni, A., Leone, G., Sica, S., Martelli, M., Tabilio, A., Fioritoni, G., Majolino, I. and Mandelli, F. (2000) "Autologous peripheral blood stem cell transplantation as first fine treatment of multiple myeloma: an Italian Multicenter study", Hematologica 85, 52-58.
5. Patriarca, F., Damiani, D., Fanin, R., Grimaz, S., Geromin, A., Cerno, M., Sperotto, A., Silvestri, F., Zaja, F. and Baccarani, M. (2000) "High dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome", Hematologica 85(3), 269-274.
6. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients", Hematologica 85(5), 508-513.
7. Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R.M., Bandini, G., Motta, M.R., Testoni, N., Amabile, M., Ottaviani, E., Vianelli, N., de Vivo, A., Gozzetti, A., Tura, S. and Cavo, M. (2000) "Molecular remission after allogenic or autologous transplantation of hemopoieitic stem cell for multiple myeloma", J. Clin. Oncol. 18(11), 2273-2281.
8. Maisnar, V., Touskova, N., Maly, J., Krejsek, J., Kmonicek, M. and Kopecky O. (2002) "Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma", Vnitr. Leuk. 48(4), 290-297.
9. Fakan, F., Boudova, L. and Hejda, C. (2002) "Syndecan-1 (CD138) an immunohistochemical marker of plasma cell tumors", Cesk. Path. 38(1), 33-36.
10. Bayer-Garner, I.B., Joseph, L., Sanderson, R.D. and Smoller, B.R. (2003) "Expression of syndecan-1 is a senesitive marker for cutaneous plasmacytoma", J. Cutan. Pathol. 30(1), 18-22.
11. Sanderson, R.D. and Borset, M. (2002) "Syndecan-1 in B lymphoid malignancies", Ann. Hematol. 81(3), 125-135.
12. , Blood 99(4), 1405-1410.
13. Ridley, R.C., Xiao, H., Hata, H., Woodliff, J., Epstein, J. and Sanderson, R.D. (1993) "Expression of syndecan regulates human myeloma plasma cell adhesion to Type I collagen", Blood 81(3), 767-774.
14. Liebersbach, B.F. and Sanderson, R.D. (1994) "Expression of syndecan-1 inhibits cell invasion into type I collagen", J. Biol. Chem. 269(31), 20013-20019.
15. Teoh, G. and Anderson, K.C. (1997) "Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma", Hematol. Oncol. Clin. North Am. 11(1), 27-42.
16. Yang, Y., Yaccoby, S., Liu, W., Langford, J.K., Pumphrey, C.Y., Theus Epestein, J. and Sanderson, R.D. (2002) "Soluble syndecan-1 promotes growth of meloma tumor in vivo", Blood 100(2), 610-617.
17. Seidel, C., Sundan, A., Hjorth, M., Turesson, I., Dahl, I.M., Abildgaard, N., Waage, A. and Borset, M. (2000) "Syndecan-1: a new independent prognostic marker in multiple myeloma", Blood 95, 388-392.
18. Seidel, C., Borset, M., Turesson, I., Abildgaard, N., Sundan, A. and Waage, A. (1998) "Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study group", Blood 91(3), 806-812.
19. Dhodapkar, M.W., Kelly, T., Theus, A., Athota, A.B., Barlogie, B. and Sanderson, R.D. (1997) "Elevated levels of shed syndecan-1 correlate with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma", Br. J. Haematol. 99, 368-371.
20. Salmon, S.E. and Smith, B.A. (1970) "Immunoglobulin synthesis and total body tumor cell memberane in IgG multiple myeloma", J. Clin. Investig. 88, 1114-1118.
21. Min, R., Li, Z., Epstein, J., Barlogie, B. and Yi, Q. (2002) "β2 microglobulinas a negative growth regulator of myeloma cells", Br. J. Haematol. 118(2), 495-505.
22. Dhodapkar, M.V., Abe, E., Theus, A., Lacy, M., Langford, J.K., Barlogie, B. and Sanderson, R.D. (1998) "Syndecan-1 is a multifunctional regulator of myeloma pathobiology; control of tumor survival, growth and bone cell differentiation", Blood 91(8), 2679-2688.
23. Li, X., Zhang, X., Lu, Z., et al. (2001) "Relative study of soluble syndecan-1 and prognosis of patients with multiple myeloma", Zhonghua Xue Ye Xue Za Zhi 22(6), 303-305, [absract] article in chinesse.
24. Holen I., Drury, N.L., Hargreaves, P.G. and Croucher, P.I. (2001) "Evidence of a role for a non-matrix-type metalloproteinase activity in shedding of syndecan-1 from human myeloma. cells", Br. J. Haematol. 114(2), 414-421.
25. Kelly, T., Borset, M., Abe, E., Gaddy-Kurten, D. and Sanderson, R.D. (2000) "Matrix metalloproteinases in multiple myeloma", Leuk. Lymphoma 37(3-4), 273-281.
26. Kaushal, G.P., Xiong, X., Athota, A.B., Rozypal, T.L., Sanderson, R.D. and Kelly, T. (1999) "Syndecan-1 expression suppresses the level of myeloma matrix metalloproteinase -9", Br. J. Haematol. 104(2), 365-373.
27. Bayer-Garner, I.B., Sanderson, R.D., Dhodapkar, M.V., Owens, R.B. and Wilson, C.S. (2001) "Syndecan(CD138): immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions", Mod. Pathol. 14(10), 1052-1058.
28. Wijdenes, J., Vooijs, W.C., Clement, C., Post, J., Morard, F., Vita, N., Laurent, P, Sun, R.X., Klein, B. and Dore, J.M. (1996) "A plasmacyte selective monoclonal antibody (B-B4) recognizes syndecan-1" Br. J. Haematol. 94(2), 318-323.
29. Jourdan, M., Ferlin, M., Legouffe, E., Horvathova, M., Liautard, J., Rossi, J.F., Wijdenes, J., Brochier, J. and Klein, B. (1998) "The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells", Br. J. Haematol. 100(4), 637-646.
30. Subramanian, S.V, Fitzgerald, M.L. and Bernfield, A (1997) "Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation", J. Biol. Chem. 272(23),